What is Dynacure?
Founded in 2016, Dynacure is a clinical-stage biopharmaceutical company dedicated to creating and commercializing innovative treatments for patients suffering from rare diseases. The company's focus is on addressing conditions with limited or no existing therapeutic options, aiming to significantly improve patient outcomes. Dynacure's strategic approach involves advancing its pipeline through rigorous clinical development, positioning it as a key player in the rare disease therapeutic landscape.
How much funding has Dynacure raised?
Dynacure has raised a total of $110M across 2 funding rounds:
Series A
$55M
Series C
$55M
Series A (2018): $55M with participation from Andera Partners, Kurma Partners, Pontifax, Bpifrance, and IdInvest Partners
Series C (2020): $55M led by Andera Partners, Bpifrance, Tekla Capital Management, and Perceptive Advisors
Key Investors in Dynacure
Andera Partners
Andera Partners is a European investment management company that provides financing for companies at various stages of development, with a focus on life sciences and technology sectors. They are known for their active involvement in supporting portfolio companies through strategic guidance and capital.
Bpifrance
Bpifrance is a French public investment bank that finances companies at every stage of their development, supporting innovation projects and international expansion. They offer a range of financial products including credit, guarantees, and equity.
Tekla Capital Management
Tekla Capital Management is an investment firm that focuses on providing capital to companies, particularly within the healthcare and life sciences industries. They aim to support the growth and development of innovative ventures.
What's next for Dynacure?
With the recent strategic investment, Dynacure is poised to accelerate its development programs and expand its operational capabilities. The substantial enterprise-level funding provides the necessary resources to advance its clinical-stage assets through key milestones. This capital infusion is expected to fuel further research and development, potentially leading to new therapeutic breakthroughs and strengthening Dynacure's market position in the competitive rare disease sector. The company's trajectory suggests a focus on scaling its operations and preparing for future commercialization efforts.
See full Dynacure company page
